Trial Profile
Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Kangstem Biotech
- 12 Apr 2017 New trial record